Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors

Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors

Bibliographic Details
Main Authors:	Shruti Gupta, Tiffany Caza, Sandra M. Herrmann, Vipulbhai C. Sakhiya, Kenar D. Jhaveri
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024921015588

Similar Items

Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
by: Kenar D. Jhaveri, et al.
Published: (2017-01-01)

Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer
by: Ayana Shikanai, et al.
Published: (2022-01-01)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
by: Paul E. Hanna, et al.
Published: (2023-08-01)

Acute Kidney Injury in the Patient with Cancer
by: Alejandro Meraz-Munoz, et al.
Published: (2021-03-01)

Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review
by: Ling-Yi Xu, et al.
Published: (2023-02-01)

Clinicopathological Features of Anticancer Drug-induced Kidney Injury
by: GENG Tonghui, LI Han, JIN Jingjing, CHENG Meijuan, ZHANG Shenglei, BAI Yaling, XU Jinsheng
Published: (2022-11-01)

The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
by: Xuan-Bing Liang, et al.
Published: (2023-08-01)

CDK 4/6 inhibitors for the treatment of meningioma
by: Jacob S. Young, et al.
Published: (2022-07-01)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
by: Abeer J. Al-Qasem, et al.
Published: (2022-09-01)

Clinicopathological Manifestations of Kidney Injury in Leukemia
by: WANG Yina, DONG Bao, LI Xin, SHAO Chunying, ZUO Li, WANG Mei, YAN Yu
Published: (2022-03-01)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
by: Ran Sun, et al.
Published: (2022-04-01)

733 Immunological mechanisms of resistance to CDK4/CDK6 inhibitors in breast cancer
by: Silvia Formenti, et al.
Published: (2021-11-01)

Relationship between ZWINT and CDK2 expression and clinicopathological features and their diagnostic values in breast cancer
by: Zhang Fangfang, Han Yifei, Wang Jingnan, Zou Yan, Ying Li, Li Na
Published: (2024-01-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors
by: Joe-Elie Salem, et al.
Published: (2021-10-01)

Recent Progress in CDK4/6 Inhibitors and PROTACs
by: Hao Wang, et al.
Published: (2023-12-01)

Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
by: Nadia Ashai, et al.
Published: (2023-03-01)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
by: Inês Gomes, et al.
Published: (2023-10-01)

Pitfalls of Current Diagnostic Criteria of Tumor Lysis Syndrome
by: Naji Alhamid, et al.
Published: (2024-03-01)

A letter to the Master Clinician [v1; ref status: indexed, http://f1000r.es/2m0]
by: Kenar D. Jhaveri
Published: (2014-01-01)

A letter to the Master Clinician [v2; ref status: indexed, http://f1000r.es/2zh]
by: Kenar D. Jhaveri
Published: (2014-02-01)

Machine learning methods for prediction of CDK-inhibitors.
by: Jayashree Ramana, et al.
Published: (2010-01-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
by: Tatjana Arsenijevic, et al.
Published: (2023-02-01)

CDK4/6 inhibitor resistance: A bibliometric analysis
by: Jiayuecheng Pang, et al.
Published: (2022-12-01)

Cyclin-dependent kinase (CDK) 4/6 inhibitors in oncology
by: Karamitrousis Evangelos, et al.
Published: (2020-04-01)

Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.
by: Ellis, M, et al.
Published: (1999)

Large-cell neuroendocrine carcinoma of the kidney: Clinicopathologic features
by: Ranganath Ratnagiri, et al.
Published: (2009-01-01)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
by: Lindsey R. Pack, et al.
Published: (2021-06-01)

Clinicopathological Relevance of PAX8 Expression Patterns in Acute Kidney Injury and Chronic Kidney Diseases
by: Maja Zivotic, et al.
Published: (2022-08-01)

Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Mellitus and CKD
by: Lubaina Presswala, et al.
Published: (2019-09-01)

CDK9 inhibitors in acute myeloid leukemia
by: Silvia Boffo, et al.
Published: (2018-02-01)

Kidney and Urinary Tract Involvement in Chronic Myelomonocytic Leukemia
by: Rose Mary Attieh, et al.
Published: (2024-02-01)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
by: Michela Piezzo, et al.
Published: (2020-09-01)

Determinants of response to CDK4/6 inhibitors in the real-world setting
by: Agnieszka K. Witkiewicz, et al.
Published: (2023-09-01)

Development of CDK4/6 Inhibitors: A Five Years Update
by: Alessandra Ammazzalorso, et al.
Published: (2021-03-01)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
by: Angeliki Andrikopoulou, et al.
Published: (2021-06-01)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
by: Amrallah A. Mohammed, et al.
Published: (2019-07-01)

The application and prospect of CDK4/6 inhibitors in malignant solid tumors
by: Qi Du, et al.
Published: (2020-05-01)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
by: Yilan Yang, et al.
Published: (2020-09-01)

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
by: ZHANG Baihong, et al.
Published: (2019-01-01)